Publication:
Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Placeholder

Organizational Units

Program

Authors

Authors

GÜMÜŞ, MAHMUT
Sezer, A.
Kilickap, S.
ÖZGÜROĞLU, Mustafa
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source:

Keywords:

Keywords

Citation

Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021

Endorsement

Review

Supplemented By

Referenced By

6

Views

0

Downloads


Sustainable Development Goals